Novavax Stock News

Millions of Novavax vaccinations have arrived in Australia giving the country a new weapon against Covid.

Millions of Novavax vaccinations have arrived in Australia giving the country a new weapon against Covid.

The first shipment of Novavax lands in Australia ahead of the rollout later this month.

Here''s your TL;DR for this morning''s news.

News that Australia has received its first shipment of Novavax''s Covid-19 vaccine has NVAX stock taking off nearly 9% in today''s trading.

When the stock market crashes and your favorite stocks are getting killed, it''s a good idea to add to your long-term winners.

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Novavax, Inc. (NASDAQ:NVAX) has had a tough year with losses of approximately 68%. It has already declined about 37% year-to-date, as well. However, as of Feb. 3, 2022, the stock has a 5-day return of nearly 25%. This increased volatility in the stock price is primarily news-driven. Source: vovidzha / Shutterstock.com Novavax is trying to. The post 2022 Could be a Success or a Lost Opportunity for Novavax appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Germany''s expert panel on vaccine use has recommended Novavax Inc''s (NASDAQ: NVAX ) protein-based COVID-19 vaccine for primary immunization for people over 18 years. The advisory group known as STIKO said a booster shot should still be given with an mRNA vaccine, reported Reuters. mRNA technology is behind the two most commonly used COVID-19 vaccines from - Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc (NASDAQ: MRNA ). Novavax''s COVID-19 vaccine NVX-CoV2373 is Full story available on Benzinga.com

This article was originally published on TipRanks.com. The post Novavaxs COVID-19 Vaccine Gets Conditional Approval in the UK; Shares Jump 4.4% appeared first on Smarter Analyst .

A fourth Covid-19 vaccine has been provisionally approved for use in New Zealand.

New Zealand approves Novavax’s two-dose COVID-19 vaccine for use in adults

Novavax''s COVID-19 vaccine, NVX-CoV2373, was granted provisional authorization by New Zealand''s Medsafe

Novavax Inc said on Thursday it had received provisional approval from New Zealand''s medicines regulator for its COVID-19 vaccine, Nuvaxovid, for individuals 18 years of age and older.

Ministers will still need to decide whether the two-dose vaccine will be used in New Zealand.